Impact Events
MoreDate | Lead Company | Event | Type | Approval Change | Approval Likelihood |
---|---|---|---|---|---|
3/15/24 | Johnson & Johnson (JNJ) | Carvykti for Multiple Myeloma (MM) | Subscribers Only | Subscribers Only | Subscribers Only |
3/15/24 | Bristol Myers Squibb (BMY) | Abecma for Multiple Myeloma (MM) | Subscribers Only | Subscribers Only | Subscribers Only |
3/14/24 | Aquestive Therapeutics (AQST) | Anaphylm for Anaphylaxis | Subscribers Only | Subscribers Only | Subscribers Only |
3/14/24 | OcuTerra | OTT166 for Diabetic Retinopathy (Ophthalmology) | Subscribers Only | Subscribers Only | Subscribers Only |
3/14/24 | Madrigal Pharmaceuticals (MDGL) | Rezdiffra for Non-Alcoholic Steatohepatitis (NASH) | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
MoreExpected Date Range | Lead Company | Drug | Expected Catalyst |
---|---|---|---|
12/26/23 | Subscribers Only | Subscribers Only | Trial Announcement - Initiation |
12/31/23 | Subscribers Only | Subscribers Only | Partnership - Acquisition Completion |
02/16/24 | Subscribers Only | Subscribers Only | Partnership - Acquisition Completion |
02/16/24 | Subscribers Only | Subscribers Only | Partnership - Acquisition Completion |
02/29/24 | Subscribers Only | Subscribers Only | Partnership - Acquisition Completion |